Early prediction of progression
| Study . | n . | Baseline . | 3 mo . | 6 mo . | 12 mo . | End point . |
|---|---|---|---|---|---|---|
| Historical | ||||||
| Mahon et al (IFN)121 | 116 | NA | CHR | NA | NA | MCR |
| Baccarani et al (imatinib, review)8 | NA | NA | CHR | NA | CCR | OS |
| Baseline | ||||||
| Hasford et al (EUTOS)102 | 2060 | High risk | NA | NA | NA | CCR* |
| Fabarius et al15 | 1151 | Major route ACA | NA | NA | NA | OS |
| Verma et al103 | 1292 | P190BCR-ABL | NA | NA | NA | PFS |
| Clonal evolution | ||||||
| Baccarani et al (review)8 | NA | NA | NA | Any time | NA | OS |
| Response | ||||||
| Hanfstein et al122 | 692 | NA | MR 10%, MCR | MR 1%, CCR | NA | OS |
| Hehlmann et al42 | 1014 | NA | NA | NA | MMR (MR 0.1%) | OS |
| Marin et al123 | 282 | NA | MR 9.84% | MR 1.67% | MR 0.53% | OS |
| Jabbour et al124 | 435 | NA | MCR | CCR | NA | OS |
| Study . | n . | Baseline . | 3 mo . | 6 mo . | 12 mo . | End point . |
|---|---|---|---|---|---|---|
| Historical | ||||||
| Mahon et al (IFN)121 | 116 | NA | CHR | NA | NA | MCR |
| Baccarani et al (imatinib, review)8 | NA | NA | CHR | NA | CCR | OS |
| Baseline | ||||||
| Hasford et al (EUTOS)102 | 2060 | High risk | NA | NA | NA | CCR* |
| Fabarius et al15 | 1151 | Major route ACA | NA | NA | NA | OS |
| Verma et al103 | 1292 | P190BCR-ABL | NA | NA | NA | PFS |
| Clonal evolution | ||||||
| Baccarani et al (review)8 | NA | NA | NA | Any time | NA | OS |
| Response | ||||||
| Hanfstein et al122 | 692 | NA | MR 10%, MCR | MR 1%, CCR | NA | OS |
| Hehlmann et al42 | 1014 | NA | NA | NA | MMR (MR 0.1%) | OS |
| Marin et al123 | 282 | NA | MR 9.84% | MR 1.67% | MR 0.53% | OS |
| Jabbour et al124 | 435 | NA | MCR | CCR | NA | OS |
Patients at increased risk of progression can be detected by baseline markers, clonal evolution, and early molecular or cytogenetic response indicators. Failure to reach the defined response landmarks at 3, 6, and 12 months identifies a group of high risk patients with higher progression risks (25%-33% of patients at 3 months122,123 ) who might benefit from an early change of therapy. Percentages are according to international scale.130
CHR indicates complete hematologic remission; MCR, major cytogenetic remission; NA, not applicable; OS, overall survival; ACA, additional cytogenetic aberrations; PFS, progression-free survival; and MR, molecular response.
CCR at 18 months.